Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN 55905, USA.
J Vasc Surg. 2012 Feb;55(2):406-12. doi: 10.1016/j.jvs.2011.08.047. Epub 2011 Nov 21.
Small numbers of patients have advanced renal and mesenteric vascular disease requiring treatment. Open surgical treatment has been considered high risk, and the advent of endovascular intervention has affected management. This study evaluated the safety and long-term efficacy of concomitant mesenteric and renal revascularization with open techniques.
Data from 90 consecutive patients who underwent mesenteric and renal revascularization during a 30-year period were analyzed. Early and late outcomes were evaluated over two intervals: 48 in period A (1978 to 1995), concomitant open renal and mesenteric revascularization (COR; n = 46) and sequential open renal and mesenteric revascularization (SOR; n = 2); 42 in period B (1996 to 2009), 22 COR, 4 SOR, 13 sequential hybrid open/endovascular repairs (SOER), and 3 sequential endovascular repairs (SER).
There were 26 men and 64 women (median age, 67 years). Renal insufficiency was present in 24% and coronary artery disease (CAD) in 53%. Open surgical reconstruction was performed in 126 renal and 149 mesenteric arteries, with angioplasty/stenting in 15 and 8, respectively; 58 patients had concomitant aortic reconstruction (AR), and 9 had prior AR (8 in period A, 1 in period B). Hospital mortality was 8.8% overall; seven (14.5%) in period A and one (2.3%) in period B. Causes of early death were hemorrhage in three and multisystem organ failure in five. During a median follow-up of 4.5 years (range, 6 days-26.5 years), 11 patients progressed to hemodialysis (7 COR, 4 SOER), and 6 had recurrent mesenteric ischemia (4 COR, 1 SOER, 1 SER). Eight patients in period A and seven in period B required further procedures (9 renal, 9 mesenteric; 11 COR, 2 SOER, 1 SOR, 1 SER). Univariate analysis of COR patients showed CAD (P = .017) and prior AR (P = .035), but not concomitant AR (P = .366), predicted early death. Five-year survival for COR patients was 65% overall, but 74% in patients who survived the operation, with no difference between time periods (P = .55).
Concomitant open mesenteric and renal revascularization is associated with low early mortality and good long-term durability in appropriately selected patients. It remains a viable procedure, especially in patients requiring concomitant aortic reconstruction. High-risk patients with CAD or prior aortic surgery should be considered for endovascular treatment, when anatomically feasible.
只有少数患有需要治疗的晚期肾和肠系膜血管疾病的患者。开放性外科治疗被认为风险较高,而血管内介入技术的出现改变了这种治疗方法。本研究评估了开放式技术同时进行肠系膜和肾血管重建的安全性和长期疗效。
对 30 年来 90 例连续接受肠系膜和肾血管重建的患者的数据进行了分析。通过两个时间段评估早期和晚期结果:A 期(1978 年至 1995 年)48 例,同期开放式肾和肠系膜血管重建(COR;n=46)和序贯开放式肾和肠系膜血管重建(SOR;n=2);B 期(1996 年至 2009 年)42 例,22 例 COR、4 例 SOR、13 例序贯混合式开放/血管内修复(SOER)和 3 例序贯血管内修复(SER)。
26 名男性和 64 名女性(中位年龄 67 岁)。24%存在肾功能不全,53%存在冠状动脉疾病(CAD)。126 例肾动脉和 149 例肠系膜动脉进行了开放性外科重建,分别进行了血管成形术/支架置入术 15 例和 8 例;58 例患者进行了同期主动脉重建(AR),9 例患者进行了既往 AR(8 例在 A 期,1 例在 B 期)。总体住院死亡率为 8.8%;A 期 7 例(14.5%),B 期 1 例(2.3%)。早期死亡的原因是 3 例出血和 5 例多器官功能衰竭。在中位随访 4.5 年(范围 6 天至 26.5 年)期间,11 例进展为血液透析(7 例 COR、4 例 SOER),6 例再次发生肠系膜缺血(4 例 COR、1 例 SOER、1 例 SER)。A 期 8 例和 B 期 7 例患者需要进一步治疗(9 例肾、9 例肠系膜;11 例 COR、2 例 SOER、1 例 SOR、1 例 SER)。COR 患者的单因素分析显示 CAD(P=0.017)和既往 AR(P=0.035),但同期 AR(P=0.366)与早期死亡无关。COR 患者的 5 年总生存率为 65%,但手术存活患者的生存率为 74%,两个时期之间无差异(P=0.55)。
在适当选择的患者中,同期开放肠系膜和肾血管重建术具有较低的早期死亡率和良好的长期耐久性。这仍然是一种可行的手术方法,尤其是在需要同期主动脉重建的患者中。对于存在 CAD 或既往主动脉手术的高危患者,应考虑在解剖上可行的情况下进行血管内治疗。